Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population.

Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Abstract Text:

    atul kumarAtul Kumar,subijay sinhaSubijay Sinha,atul kumarAtul Kumar,subijay sinhaSubijay Sinha,

    BACKGROUND: To report the anatomic and visual acuity response after intravitreal bevacizumab (Avastin) in patients with diffuse diabetic macular edema. Design: Prospective, interventional case series study. MATERIALS AND METHODS: This study included 20 eyes of metabolically stable diabetes mellitus with diffuse diabetic macular edema with a mean age of 59 years who were treated with two intravitreal injections of bevacizumab 1.25 mg in 0.05 ml six weeks apart. Main outcome measures were 1) early treatment diabetic retinopathy study visual acuity, 2) central macular thickness by optical coherence tomography imaging. Each was evaluated at baseline and follow-up visits. RESULTS: All the eyes had received some form of laser photocoagulation before (not less than six months ago), but all of these patients had persistent diffuse macular edema with no improvement in visual acuity. All the patients received two injections of bevacizumab at an interval of six weeks per eye. No adverse events were observed, including endophthalmitis, inflammation and increased intraocular pressure or thromboembolic events in any patient. The mean baseline acuity was 20/494 (log Mar=1.338+/-0.455) and the mean acuity at three months following the second intravitreal injection was 20/295 (log Mar=1.094+/-0.254), a difference that was highly significant ( P =0.008). The mean central macular thickness at baseline was 492 microm which decreased to 369 microm ( P =0.001) at the end of six months. CONCLUSIONS: Initial treatment results of patients with diffuse diabetic macular edema not responding to previous photocoagulation did not reveal any short-term safety concerns. Intravitreal bevacizumab resulted in a significant decrease in macular thickness and improvement in visual acuity at three months but the effect was somewhat blunted, though still statistically significant at the end of six months.

    Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Publishing Authors By Initials

    a kumarA Kumar,s sinhaS Sinha,a kumarA Kumar,s sinhaS Sinha,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE: 2007 Nov-Dec

    Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Indian journal of ophthalmology

    VOLUME: 55

    Page Numbers: 451-5

    Journal Abbreviation:

    ISSN: 0301-4738

    DAY: 22

    MONTH: 10

    YEAR: 2007

    Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 405376

    Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population.

    AFFILIATION: Vitreous-Retina Service, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi - 110 029, India. atulretina@gmail.com

    Country: India

    India Research PublicationIndia Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Indian J Ophthalmol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Intravitreal bevacizumab Avastin treatment of diffuse diabetic macular edema in an Indian population Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News